Clinical efficacy and safety of Vitaros©/Virirec© (Alprostadil cream) for the treatment of erectile dysfunction

Urologia
Ignacio Moncada, Béatrice Cuzin

Abstract

Erectile dysfunction (ED) is a very common disorder with a deep impact on patients and their partners. Several options are now available for treating ED; oral pharmacotherapy with phosphodiesterase-5 (PDE5) inhibitors currently represents the first-line option for many ED patients. Vitaros©/Virirec© is new topical, non-invasive treatment for ED that offers the combination of an active drug (alprostadil, a synthetic PGE1) with a skin enhancer that improves its local absorption directly at the site of action. Vitaros©/Virirec© has a favorable pharmacodynamic profile and is poorly absorbed in systemic circulation. This makes it suitable in any circumstances and results in a reduced risk of adverse events (AEs), being systemic AEs reported in only 3% of the treated population. Its clinical efficacy has been demonstrated in both phase II and III trials, showing a global efficacy up to 83% with the 300 μg dose in patients with severe ED significantly better than placebo. Its fast onset of action together with its favorable toxicity profile and lack of interactions with other drugs makes Vitaros©/Virirec© a first-line therapeutic option for patients with ED, particularly for individuals who are reluctant to take systemic treatments or...Continue Reading

References

Jun 15, 2000·The New England Journal of Medicine·T F Lue
Oct 18, 2000·International Journal of Impotence Research·I Saenz de Tejada
Jun 21, 2001·International Journal of Impotence Research·M BraunU Engelmann
Mar 12, 2004·Expert Opinion on Pharmacotherapy·Edgardo Becher
May 8, 2004·International Journal of Pharmaceutics·Anne M WolkaB C Finnin
Nov 13, 2004·International Journal of Impotence Research·J Yeager, R M Beihn
Mar 16, 2005·Journal of Managed Care Pharmacy : JMCP·Helen Eloise Campbell
Sep 22, 2006·International Journal of Impotence Research·N MehrotraB Meibohm
Jun 5, 2007·Endocrinology and Metabolism Clinics of North America·William O BrantTom F Lue
Jun 23, 2009·The Journal of Sexual Medicine·Andre B AraujoJohn B McKinlay
Aug 7, 2009·Nature Reviews. Urology·Ahmed Magheli, Arthur L Burnett
Oct 29, 2009·Current Pharmaceutical Design·Giannitsas Konstantinos, Perimenis Petros
Mar 2, 2010·European Urology·Konstantinos HatzimouratidisUNKNOWN European Association of Urology
Apr 15, 2010·The Journal of Sexual Medicine·Ronald W LewisTaylor Segraves
Nov 3, 2010·The Journal of Sexual Medicine·Francesco MontorsiMarlene Wasserman
Aug 13, 2011·The Journal of Sexual Medicine·Thomas G TravisonMichael S Sand
Sep 14, 2012·The Journal of Sexual Medicine·John P MulhallEdgardo F Becher
Oct 9, 2012·Lancet·Rany Shamloul, Hussein Ghanem
May 10, 2013·The World Journal of Men's Health·Nam Cheol ParkHyun Jun Park
Dec 10, 2013·The Journal of Sexual Medicine·Emmanuele A JanniniChiara Simonelli
Dec 27, 2013·Expert Opinion on Pharmacotherapy·Vishwanath Hanchanale, Ian Eardley

❮ Previous
Next ❯

Citations

Dec 31, 2015·Current Opinion in Urology·Kyriakos MoisidisKonstantinos Hatzimouratidis
Jul 28, 2018·International Journal of Impotence Research·I MoncadaJ Romero
Jan 13, 2021·Medicines·Charalampos Thomas, Charalampos Konstantinidis
Jan 29, 2020·Pharmacology & Therapeutics·Emma MitidieriRaffaella Sorrentino
Sep 14, 2021·Diabetes/metabolism Research and Reviews·Giuseppe DefeudisDaniele Gianfrilli
Dec 5, 2021·The Senior Care Pharmacist·Justyna Sudyka, Jeannette Y Wick

❮ Previous
Next ❯

Software Mentioned

Vitaros ©
Virirec
Vitaros

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.